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“CDC’s laboratory scientists are at the heart of our work to protect
America on a 24/7 basis. CDC could not succeed without them. State and 
local public health departments, health care professionals, and many
others rely on our laboratory scientists for specialized testing,
consultation, and new technologies to address a wide and growing
spectrum of health threats. CDC is the de facto reference laboratory for 
the United States and for the entire world, an invaluable and 
indispensable resource.”
—	 Thomas R. Frieden, MD, MPH 
Director, Centers for Disease Control and Prevention
In Senate Report 112-84, which accompanied the Fiscal Year (FY) 2012 appropriations bill for 
the U.S. Departments of Health and Human Services, Labor, Education, and related agencies, the 
Senate Committee on Appropriations stated,
“The Committee requests a report to Congress no later than 120 days 
after the enactment of this act that details CDC’s various internal 
laboratory activities and associated funding levels.”
The Centers for Disease Control and Prevention (CDC) has prepared this report in response to 
the committee’s request. The body of the report is organized into 21 sections that correspond 
with the standard format of the CDC budget documents with which the Committee is familiar. 
Each section addresses a specific CDC budget activity and its associated internal laboratory
activities. The report encompasses the majority of CDC’s laboratory activities. Relevant 
definitions and descriptions of laboratory activities not addressed appear in the Explanation and 
Definition of CDC’s Laboratory Activities section that follows. 
Overview of CDC Laboratories
CDC is committed to keeping America safe from threats to its health, safety, and security, 
whether foreign or domestic. CDC promotes health and quality of life domestically and globally
by preventing and controlling disease, injury, and disability. Achieving excellence in laboratory
science and in delivering laboratory services is key to fulfilling CDC’s mission. 
CDC’s laboratories are integral elements of its prevention and control programs that address 
infectious and chronic diseases, birth defects and developmental disabilities, and environmental 
and occupational health. These programs cannot succeed without the actionable information and 
knowledge generated by CDC’s laboratory scientists, many of whom are nationally or 
internationally recognized as preeminent experts in their fields.
Thanks in part to the laboratories it operates, CDC has been able to
•	 identify and take action to address new disease threats (e.g., the influenza strain that erupted 
into the 2009 pandemic influenza A [H1N1] and the novel virus that triggered severe acute 
























   
•	 track the emergence of drug-resistant infections and develop new ways to counter these 
threats; 
•	 confirm the sources of foodborne disease outbreaks (e.g., those associated with cantaloupes 
in 2011 and eggs in 2010), and advise industry, the Food and Drug Administration (FDA), 
and states on corrective actions;
•	 serve as World Health Organization (WHO) Collaborating Centers (e.g., for influenza, 
malaria, tularemia, rotavirus, rabies, poxviruses, and viral hemorrhagic fevers) and 
participate in global health networks; 
•	 address priorities in human immunodeficiency virus (HIV) diagnosis, prevention, and 
treatment to reduce HIV-related illness and death in the United States and internationally;
•	 determine and address the causes of flare-ups of vaccine-preventable diseases (e.g., the spike 
in U.S. measles cases that appeared in early 2011 after 15 years of low incidence);
•	 examine suspicious substances to determine if they pose any threats and report findings so 
that appropriate actions to protect the public can be taken (e.g., the 2001 anthrax attacks);
•	 test for potential health dangers stemming from toxic releases (e.g., the Deepwater Horizon 
oil spill in 2010) and provide scientifically based information on their health implications to 
the public and to decision makers;
•	 collect objective data for use in designing interventions to prevent and control disease and 
disability (e.g., through the National Health and Nutrition Examination Survey [NHANES],
the only U.S. collection of biologic samples related to nutrition and health on a 
populationwide basis); 
•	 ensure accuracy of the tests state public health laboratories use to screen newborns in the 
United States for medical conditions that can lead to lifelong disability or death if not 
detected; and
•	 develop and disseminate authoritative public health guidelines (e.g., for the respirators that 
protect millions of health care professionals, first responders, and industrial workers from 
airborne viruses and pollutants). 
CDC’s laboratories are distinct from the many commercial, hospital, and physician-office 
laboratories that perform tests related to individual patients. CDC has the unique ability to 
develop and perform highly sophisticated, cutting-edge tests important for monitoring population 
health and to serve as the last-resort reference laboratory, able to confirm or rule out a new virus 
or other pathogens. Some of this work is performed in high-containment laboratories where
scientists work with especially dangerous infectious and chemical agents. CDC is also uniquely
capable of establishing definitive standards for laboratory testing, including tests used in both 




















   
 
   
 
complementary disciplines on solving complex public health problems. A recent example is the 
effort to develop and validate new mass spectrometry test methods for detecting human exposure
to botulinum toxin ― a result of collaboration between CDC’s Environmental Health 
Laboratory, which specializes in assessing chemical exposures, and Foodborne Disease
Laboratory, which specializes in biologic testing. The new test methods will support responses to 
biologic or chemical terrorist attacks and foodborne illness outbreaks, as well as investigations of 
potentially contaminated cosmetic products.
CDC laboratory scientists work closely with their programmatic partners within CDC, including
epidemiologists and other colleagues across a wide spectrum of disciplines. In turn, CDC relies 
on the work its laboratory scientists conduct across multiple domains that are crucial to the 
agency’s priorities and to its vital contribution to national security. Examples include the 
following:
•	 Surveillance — Testing to track trends in diseases and other health threats, monitor national 
health status, and evaluate the effectiveness of vaccines, treatments, infection control 
programs, and other public health and medical strategies.
•	 Emergency Response — Testing for rapid identification of the causes of disease outbreaks 
from natural or human-made biologic threats (BT), chemical threats (CT), or radiologic 
threats (RT) to ensure rational treatment decisions are made.
•	 Standards Setting — Establishing technical and scientific standards for public health and 
clinical laboratory tests (e.g., for the millions of cholesterol tests performed annually in our 
nation’s hospitals and clinical laboratories, and for antimicrobial susceptibility testing).
•	 Quality Assurance — Developing, promoting, and evaluating standards and guidelines for 
public health and clinical laboratories, and providing technical assistance and reliable 
reference materials to support test validation, quality control, and proficiency testing.
•	 New Product Development— Applying research findings to develop new types of tests, 
new vaccines, and other products, many of which are licensed to private companies to 
manufacture and make available through the commercial marketplace.
•	 Health System Support — Providing scientific, technical, and financial assistance to help 
state and local public health agencies, health care providers, nonprofit groups, federal 
agencies, and other partners improve their laboratory practices and strengthen their 
laboratory systems.
Partnerships 
CDC relies heavily on collaboration with other federal agencies, state and local public health 
departments, health care organizations, and other domestic and international partners to 


























laboratory professionals and scientists in other U.S. Department of Health and Human Services
operating divisions, the U.S. Department of Homeland Security, the U.S. Department of 
Defense, the Federal Bureau of Investigation, the U.S. Agency for International Development 
(USAID), and the U.S. Department of Agriculture (USDA), among other federal agencies; WHO 
and ministries of health worldwide; and industry and nongovernmental organizations (e.g., the 
Association of Public Health Laboratories).
State and local public health laboratories protect health in their jurisdictions and partner closely
with CDC as critical parts of the nation’s public health laboratory safety net. Among other 
services, state and local public health laboratories perform many public health reference tests, 
confirming or ruling out patient diagnoses, advising providers on the significance of patient test 
results, and simultaneously using test results to monitor community health trends. Of special note 
are the critical roles they play in detecting the onset of threats at the front line and in providing
surge capacity, helping to manage the high number of tests required during public health 
emergencies (e.g., the 2009 influenza A H1N1 pandemic).
CDC provides critical support to state and local public health laboratories by designing,
developing, and transferring high-quality testing practices to them and by providing technical 
consultation, training, financial assistance, and high-priority supplies not available from other
sources. In addition, CDC has sponsored creation and operation of national networks for disease 
cluster detection and investigation, rapid communication, and test result validation during
foodborne disease outbreaks (e.g., PulseNet) and in response to BTs or CTs or other public 
health emergencies (i.e., the Laboratory Response Network [LRN]). PulseNet enables state and 
local public health agencies to detect clusters of illnesses in one or many states rapidly by
comparing DNA fingerprints of bacteria from ill patients through the use of an online pattern 
database maintained by CDC. These disease clusters often represent silently developing
foodborne disease outbreaks that can be controlled if detected early. More importantly, PulseNet­
detected outbreaks provide industry and regulators the information they need to fix problems in 
our food supply that would otherwise go unnoticed. LRN — comprising 162 laboratories, most 
of which can confirm the detection of BT agents and a subset of which have additional capacity
to do CT testing — expands and leverages the capacity of the public health laboratory system to 
respond to public health threats and emergencies. An estimated 85% of the U.S. population lives 
within 100 miles of an LRN member laboratory, ensuring broad access to testing during public 
health emergencies. Other federal agencies (e.g., the U.S. Department of Defense, the Federal 
Bureau of Investigation, FDA, USDA, the U.S. Department of Energy, and the U.S. 
Environmental Protection Agency), collaborate with the network and coordinate response 
activities through the Integrated Consortium of Laboratory Networks. Public health laboratories 
in Australia, Canada, Mexico, and the United Kingdom also participate in LRN.
University- and industry-based scientists and members of scientific and professional associations 
also are valuable partners for CDC’s laboratory scientists. They bring important viewpoints from 
relevant disciplines and contribute new knowledge from research and front-line industry and 
clinical experience. In turn, CDC’s laboratory scientists use multiple channels to disseminate 
information to these partners about the new tests, improved testing methods, and laboratory best 


























   
Laboratory Outreach Communication System and CDC’s Morbidity and Mortality Weekly 
Report, among others. In addition, CDC maintains and continually expands its invaluable 
collections of unique biologic specimens that CDC scientists and colleagues in universities and 
other settings use for research into the causes of disease and for development of new medical and 
public health interventions.
Explanation and Definition of CDC’s Laboratory Activities
For the purposes of this report, internal laboratory activities are defined as laboratory-related 
activities that CDC employees and contractors conducted during FY 2011 in the United States, 
primarily at CDC facilities, and which were funded by the budget activities that appear in the 
accompanying table. Those facilities are located in the Atlanta, Georgia, metropolitan area and in 
Anchorage, Alaska; Ft. Collins, Colorado; Cincinnati, Ohio; Pittsburgh, Pennsylvania; San Juan, 
Puerto Rico; Spokane, Washington; and Morgantown, West Virginia.
This report addresses testing and applied research activities, as well as selected scientific, 
technical, and laboratory support services. In general, support services include activities such as
oversight and implementation of CDC’s policy on dual-use research of concern; management of 
CDC’s central collection of more than 6 million biologic specimens for use by CDC and 
extramural researchers; laboratory security and worker safety protection services; provision of 
bioinformatics and information technology services; and provision and maintenance of physical 
facilities. They also include assistance in complying with federal regulatory mandates (e.g., the 
Clinical Laboratory Improvement Amendments, diagnostic device regulations, and the Select 
Agents and Toxins regulations). The Emerging Infectious Diseases, Public Health Scientific 
Services, and Public Health Preparedness and Response sections of this report include 
information regarding laboratory support services funded from these three appropriations.
This report also addresses domestically based CDC laboratory activities that support external 
partners, including laboratories operated by ministries of health in other countries. Support for 
external partners includes provision of laboratory technical support and training, program 
administration, and cooperative agreement management. Many of these activities advance 
CDC’s global health priorities. Several sections of this report (e.g., the Global Health sections) 
include descriptions of domestic CDC laboratory activities that support overseas activities. 
Exclusions
Two types of laboratory-related activities that receive funds appropriated to CDC do not appear 
in this report, explained as follows:
Domestic Laboratory-Related Activities Conducted by Grantees — This report does not 
provide information on laboratory-related activities that state and local public health departments 
or extramural researchers conduct with funding they receive from CDC through cooperative 
agreements or other mechanisms. However, activities that CDC employees and contractors 
conduct in support of those grantees (i.e., managing cooperative agreements) are referenced 




















Global Laboratory Activities — CDC supports multiple laboratories located in other countries 
and also helps to build and operate global laboratory networks (e.g., the Global Polio Laboratory
Network, which supports worldwide poliovirus surveillance). This report does not address these 
overseas activities or those of other CDC global laboratory networks. However, where 
appropriate, it provides information about CDC’s domestically based support for such activities, 
as noted previously.
FY 2011 Funding for CDC Internal Laboratory Activities
The accompanying table indicates that CDC obligated $412,029,029 to its internal laboratory
activities during FY 2011. These funds derived from three sources, as follows: 
• CDC direct budget authority ($336,602,298 total);
• the U.S. Public Health Service Evaluation Fund ($39,648,974 total); and 
• the Public Health and Social Services Emergency Fund ($35,777,757 total).
The table (next page) is organized according to the format of CDC’s FY 2011 operating plan.
Certain internal CDC laboratory activities are supported by funds that other federal agencies 
transfer to CDC. Such activities are not included in this report, with the exception of those 
supported by the U.S. Public Health Service Evaluation Fund and the Public Health and Social 
Services Emergency Fund. Also excluded are laboratory activities supported by no-year funds 







FY 2011 Funding for CDC Internal Laboratory Activities 
Budget Activity Total 
Immunization and Respiratcry Diseases 
Budget Authority (BA) $ 5,364,537 
Public Health and Social Services Emergency Fund* $ 35,777,757 
$ 41,142,294 
m Y/AIDS, Viral Hepatitis, STD, and TBPrevention-BA 
Domestic m Y/AIDS $ 10,792,414 
Viral Hepatitis $ 3,304,900 
Sexually Transmitted Diseases (STDs) $ 4,154,881 
Tuberculosis (TB) $ 4,888,188 
$ 23,140,383 
Emerging and Zcxmotic Infectious Diseases - BA 
Vectorbome Diseases $ 8,970,182 
Lyme Disease $ 3,669,162 
Food Safety $ 6,979,036 
Chronic Fatigue Syndrome $ 3,362,953 
Emerging Infectious Diseases $ 55,335,645 
Other (Antimicrobial Resistance and Hantavirus/Special Pathogens) $ 7,963,416 
$ 86,280,394 
Clrronic Disease Prevention and Health Promotion - BA $ 6,035,291 
Birth Defects, Developmental Disabilities, Disability and Health - BA $ 2,540,629 
Environmental Health - BA 
Environmental Health Laboratory $ 32,422,706 
Healthy Homes/Childhood Lead Poisoning $ 781,512 
$ 33,204,218 
Public Health Scientific Services 
Budget Authority $ 4,992,551 
Public Health Service Evaluation $ 3,752,455 
$ 8,745,006 
Occupational Safety and Health 
Budget Authority $ 105,066,718 
Public Health Service Evaluation $ 35,896,519 
$ 140,963,237 
Global Health - BA 
Global AIDS Program $ 9,769,770 
Global ImmlU1ization Program $ 4,064,530 
Global Disease Detection and Emergency ResJXlllse $ 3,718,221 
Parasitic Diseases and 1\1alaria $ 10,256,991 
$ 27,809,512 
Public Health Preparedness and Response - BA $ 42,168,065 
CDC Total $ 412,029,029 
BA subtotal $336,602,298 
Public Health Service Evaluation subtotal $39,648,974 
Public Health and Social Services Emer~ency Fund subtotal $35, 777,757 





























BUDGET ACTIVITY — IMMUNIZATION AND RESPIRATORY DISEASES
National vaccine programs and policies rely on a foundation of strong science, which is essential 
for vaccine policy decision making and for evaluating vaccination recommendations after they
are implemented. A comprehensive immunization program requires national-level scientific 
expertise in laboratory sciences and services to monitor preventable disease rates, identify
emerging new threats, track and respond to outbreaks, and evaluate vaccine effectiveness.
CDC efforts have helped reduce the occurrence and impact of multiple vaccine-preventable 
diseases, increased immunization coverage rates, and improved vaccine safety surveillance and 
research. Continual changes in influenza and other respiratory viruses require relentless tracking
of emerging strains to ensure vaccines are effective as well as monitoring increasing importation 
of vaccine-preventable diseases that affect vulnerable populations. 
Selected Laboratory Activities in FY 2011
Vaccine-Preventable Diseases
For each annual U.S. birth cohort vaccinated against 13 diseases in accordance with the schedule 
adopted by CDC, approximately 42,000 lives are saved; 20 million cases of disease are
prevented; $13.6 billion in direct costs are saved; and $68.9 billion in direct plus indirect 
(societal) costs are saved. CDC’s Immunization Program aims to prevent vaccine-preventable 
diseases by achieving and maintaining high immunization rates. Since 2009, national policy
recommendations have been in place in the United States to prevent a total of 17 diseases among
young children, adolescents, and adults. These diseases include measles, mumps, rubella, 
varicella and herpes zoster, rotavirus, human papillomavirus (HPV), influenza and bacterial 
meningitis, whooping cough (pertussis), diphtheria, and others.
CDC laboratories
•	 provided data and analysis on which national immunization policies are based;
•	 developed new molecular diagnostic assays for measles and mumps and assisted with their 
implementation in state and local public health laboratories to detect and control outbreaks;
•	 provided outbreak assistance and performed testing to confirm vaccine-preventable disease
occurrence;
•	 diagnosed and analyzed measles, rubella, and congenital rubella syndrome cases in the 
United States; 
•	 assessed vaccine impact and changing epidemiology for new vaccine programs (e.g., 
rotavirus and pneumococcal prevention among children and meningococcal vaccine impact 
among adolescents);



























•	 monitored changes in bacteria and viruses that can cause vaccines to become less effective 
and identified new strains for use in vaccine development; 
•	 provided evidence-based vaccine effectiveness and program impact results to demonstrate 
the need for a booster dose of meningococcal vaccine among adolescents;
•	 demonstrated impact of the childhood pneumococcal conjugate vaccine introduced in 2010
(the information is being used to formulate national policies on pneumococcal vaccine use 
among adults as well as pneumonia and meningitis treatment guidelines); and 
•	 supported development and licensure of new vaccines through characterization of pathogen 
strains (e.g., meningococcus), development of standard antibody tests (e.g., pneumococcus
and meningococcus), and monitoring trends during vaccine trials. 
Influenza
Influenza is a contagious respiratory illness caused by influenza viruses. It can cause mild to 
severe illness and death. During 1976–2006, estimates of flu-associated deaths in the United 
States range from a low of 3,000 to a high of 49,000 annually. Certain groups (e.g., older 
persons, young children, and those with certain health conditions) are at higher risk for serious 
flu-related complications. The CDC Influenza Program’s laboratory activities support detection, 
control, and prevention of influenza. 
CDC laboratories
•	 provided year-round domestic surveillance for influenza;
•	 subtyped and characterized novel influenza viruses;
•	 studied global influenza trends and virus characteristics;
•	 identified potential candidate influenza vaccine virus strains through global surveillance 
activities; 
•	 used cutting-edge technologies to engineer influenza vaccine candidate strains;
•	 provided weekly electronic reports of influenza activity to help doctors, public health 
officials, and the general public prevent influenza’s spread;
•	 helped guide development and deployment of medical countermeasures to prevent and treat 
persons affected by seasonal and future influenza pandemics; 
•	 served as the National Influenza Center for the United States and as one of five WHO 
Collaborating Centers that received and tested thousands of influenza virus samples from 
around the world to monitor for emergence and spread of new variant viruses with epidemic 
and pandemic potential, including highly pathogenic influenza A (H5N1) viruses and other 





























•	 characterized over 11,000 influenza viruses from domestic and international surveillance 
partner laboratories;
•	 participated with other WHO Collaborating Centers and National Influenza Centers in the 
yearly seasonal vaccine virus selection process for the Southern and Northern Hemispheres;
•	 sequenced and confirmed multiple novel influenza viruses, including H3N2v, which was 
confirmed in 12 cases in five states and has the potential to emerge as a circulating human 
strain; 
•	 developed a vaccine candidate strain for H3N2v influenza virus and started work with 
manufacturers to develop a vaccine, in case large-scale production becomes necessary; and
•	 developed and piloted a new influenza risk assessment tool to assess the pandemic potential 
of novel influenza viruses, which will help prioritize virologic and epidemiologic studies and 
provide information on which selection of candidate novel influenza viruses for pandemic 
vaccines can be based.
BUDGET ACTIVITY — HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION: 
DOMESTIC HIV/AIDS
Despite major advances in prevention and treatment, HIV infection remains a substantial public 
health challenge. CDC estimates that approximately 1.2 million persons in the United States 
were living with HIV at the end of 2008 and that approximately 50,000 persons are newly
infected each year.
CDC’s laboratories help advance governmentwide efforts to reduce the burden of HIV and 
acquired immunodeficiency syndrome (AIDS) in the United States, as described in the National 
HIV/AIDS Strategy. The aims of the Strategy include 
•	 reducing new HIV/AIDS infections; 
•	 increasing access to care and improving health outcomes for persons living with HIV; and
•	 reducing HIV-related health disparities. 
Early identification of HIV infection can improve access to life-saving treatment, reduce further 
transmission, and decrease health care costs. 
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 served as worldwide reference laboratories for diagnosis and drug-resistance testing for 
HIV/AIDS by providing services to both domestic and international partners (see the Global 
























•	 conducted state-of-the-art testing to advance HIV prevention, surveillance, and treatment
(e.g., testing to support early diagnosis [facilitating referral to care, as well as counseling to 
help prevent transmission], evaluating disease prognosis and response to therapy, and 
identifying drug-resistant viruses); 
•	 helped state health departments investigate cases of HIV transmission through organ 
transplantation; 
•	 patented a novel HIV drug-resistance test that can identify hidden drug-resistant viruses in 
viral subpopulations within individual patients, including patients who respond to 
antiretroviral therapy (development of drugs that can target these hidden viruses might lead 
to a cure for HIV);
•	 developed and evaluated additional novel strategies and methods for HIV detection, 
isolation, and surveillance (e.g., strategies for identifying HIV infection at earlier stages of
disease, increasing the number of persons who know their infection status and are referred 
for care, and facilitating simultaneous testing for infection with HIV and viral hepatitis); 
•	 developed rapid, user-friendly tests that can be used in the field to identify recent HIV-1 
infections and differentiate between HIV-1 and HIV-2 viruses;
•	 updated the national diagnostic algorithms for HIV testing and revised HIV screening
guidelines for organ donations; 
•	 conducted preclinical and clinical research on vaccines and methods for preventing HIV 
transmission;
•	 demonstrated that the dosage of an oral antiviral medication needed to prevent HIV infection 
might be reduced from the currently recommended daily dosing; 
•	 evaluated the threat to the U.S. blood supply posed by human herpes virus type 8 (HHV-8) 
— the etiologic agent of Kaposi's sarcoma, the most common AIDS-associated malignancy
worldwide ― and transferred HHV-8 diagnostic technology to international laboratories in 
AIDS-endemic areas of Africa (also developed an HHV-8 assay appropriate for organ donor 
screening); and
•	 conducted research studies to determine if an association exists between a retrovirus —
xenotropic murine leukemia virus-related virus — and chronic fatigue syndrome (CFS); no 
such association was identified and, consequently, two peer-reviewed journal articles from 
non-CDC investigators were retracted (see the Emerging and Zoonotic Diseases: Chronic 






























BUDGET ACTIVITY — HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION: 
VIRAL HEPATITIS
Approximately 0.8–1.4 million persons in the United States are chronically infected with 
hepatitis B virus (HBV) and 2.7–3.9 million are infected with hepatitis C virus (HCV). Many
persons are unaware of their infection, putting them at risk for cirrhosis or liver cancer and for
transmitting infection to others.
CDC’s laboratories help advance efforts across the government to reduce the U.S. burden of 
chronic viral hepatitis and associated cancers, as described in the U.S. Department of Health and 
Human Services’ Action Plan for the Prevention, Care and Treatment of Viral Hepatitis. 
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 served as a worldwide reference laboratory for diagnosis of hepatitis A, B, C, and E; 
•	 assisted U.S. states and cities and Veterans Administration medical centers in investigating
23 local outbreaks, including an outbreak of HCV infections in an outpatient clinic in 
Georgia, outbreaks of HBV infections in an assisted living facility and a psychiatric long-
term care facility in Virginia, and outbreaks of HCV infections transmitted through 
transplanted organs and tissues in Kentucky;
•	 conducted state-of-the art testing for detection of viral hepatitis antibodies and antigens and 
performed genomic and proteomic profiling of hepatitis viruses;
•	 assisted industry and academic researchers as well as health care partners by evaluating
—	 rapid screening assays for detection of antibodies to HCV, 
—	 new methods for distinguishing acute from chronic HCV infection,
—	 use of mass spectrometry methods to improve detection of HCV transmission, 
—	 the efficacy of existing vaccines in preventing HBV infections, and
—	 candidate HCV strains that might be used to develop vaccines against HCV;
•	 conducted applied research on viral transmission and pathogenesis, including an assessment 
of host genomic factors associated with chronic viral hepatitis infection;
•	 provided technical assistance on disease detection to the U.S.–Mexico Border Infectious 
Disease Surveillance program; and

























BUDGET ACTIVITY — HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION: 
SEXUALLY TRANSMITTED DISEASES (STDs) 
Approximately 19 million new STD infections occur each year in the United States, 
approximately half of which are among young persons (those aged 15–24 years). STDs exact a 
tremendous economic toll. Direct medical costs associated with STDs are estimated to be more 
than $15 billion annually.
CDC’s laboratories support public health efforts to prevent and reduce STDs and associated 
medical complications (e.g., infertility resulting from pelvic inflammatory disease caused by
chlamydia or gonorrhea; adverse pregnancy outcomes, including infant deaths or illness caused 
by neonatal herpes or congenital syphilis; and cervical cancer caused by chronic infection with 
HPV). 
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 served as worldwide reference laboratories for diagnosis of chlamydia, gonorrhea, syphilis, 
herpes simplex virus, Mycoplasma, chancroid, and HPV; 
•	 monitored emergence of antimicrobial resistance (AR) in sexually transmitted pathogens and 
notified the health care and public health communities, as needed (e.g., about emerging
resistance to cephalosporin antibiotics used to treat gonorrhea);
•	 provided reference services, diagnostic support, and staff proficiency training to state and 
local health laboratories, private laboratories, and FDA;
•	 developed and validated diagnostic tests, including new molecular tests, rapid point-of-care 
tests, and tests for molecular markers of drug resistance;
•	 provided expert consultation to physicians and physician groups, including national medical 
and nursing associations; 
•	 updated the national laboratory testing guidelines for syphilis, gonorrhea, and chlamydia (to 
be published in 2012); and 
•	 evaluated the impact of the HPV vaccination program by identifying HPV types in cancers, 
cervical precancers, and cervical specimens collected as part of NHANES (see the Public 



























BUDGET ACTIVITY — HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION: 
TUBERCULOSIS (TB) 
One third of the world’s population is infected with TB. During 2010, approximately 9 million 
persons worldwide became ill with TB and 1.4 million died.
Although TB is declining in the United States — approximately 11,000 cases were reported in 
2010 — the disease continues to affect disproportionally racial and ethnic minorities, persons 
infected with HIV, and persons who are foreign-born, including those from India, the 
Philippines, Vietnam, and Mexico. Moreover, emergence of multidrug-resistant TB (MDR TB) 
and extensively drug-resistant TB (XDR TB) is presenting new challenges for treatment and 
control. Prevention of a single case of MDR TB is estimated to save more than $250,000. 
CDC’s laboratories focus on advancing TB elimination in the United States by reducing TB
among populations at high risk and reducing TB’s global impact, including HIV-associated TB, 
MDR TB, and XDR TB.
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 served as worldwide reference laboratories for diagnosis and resistance testing for TB;
•	 managed cooperative agreements that provided technical and financial support for TB
diagnosis, surveillance, and drug-resistance testing to all 50 states, the District of Columbia, 
select cities, and eight U.S. territories and freely-associated states;
•	 operated the Molecular Detection of Drug Resistance service, which identifies cases of MDR 
TB and XDR TB; the National Genotyping Program, which provides genetic bacterial 
fingerprints of TB cases reported in the United States; and the National Genotyping
Information Management System, which analyzes laboratory and epidemiologic data to help 
identify TB cases that might be part of a widespread or multistate outbreak; 
•	 provided test evaluation and guidance that increased use of rapid molecular tests by state and 
local public health laboratories, which
—	 improved turnaround times for physicians (i.e., the time taken for a physician to receive a
laboratory result) so that patients can be treated more quickly, and
—	 facilitated public health efforts to interrupt disease transmission in communities;
•	 provided quality-assessment TB challenge samples to 40 public and private laboratories 

























•	 provided reference testing services to the CDC Tuberculosis Trials Consortium, which 
includes 20 clinical sites, and conducted
—	 applied research on drug resistance and human and bacterial genetics, and
—	 operational research to determine optimal diagnostic methods and testing algorithms for 
use in high-burden and resource-limited settings;
•	 contributed to WHO guidance on use of a new test for detecting rifamycin-resistant TB, 
which can facilitate rapid isolation and specialized treatment of patients with MDR TB; 
•	 issued recommendations on use of a new 12-dose regimen for TB preventive therapy that 
shortens and simplifies the course of treatment;
•	 served as a supranational reference laboratory in the STOP TB Partnership’s Global 
Laboratory Initiative Tuberculosis Network and worked with ministries of health and WHO 
to strengthen TB laboratory systems overseas, especially in countries that contribute to the 
burden of TB in the United States and countries that experience outbreaks of MDR TB or 
XDR TB; and
•	 led an international working group that is developing a strategy and organizational design for
an international program of TB laboratory accreditation.
BUDGET ACTIVITY — EMERGING AND ZOONOTIC INFECTIOUS DISEASES: 
VECTORBORNE DISEASES
CDC supports programs for prevention and control of diseases spread by mosquitoes, ticks, fleas, 
and other vectors in the United States and abroad (e.g., West Nile virus, dengue/dengue 
hemorrhagic fever, and Japanese encephalitis). These diseases cause tens of thousands of 
illnesses in the United States each year and millions of cases internationally, and they represent 
one of the most critical emerging threats to health in the United States. No human vaccines are 
available for the vast majority of these diseases.
These diseases can cause serious epidemics and ongoing endemic conditions. Two examples 
follow: 
•	 Since 1999, West Nile encephalitis has been the most significant arthropodborne viral illness 
in the United States, causing an estimated 1.8 million infections and more than 12,700 severe





























•	 Dengue, the most important mosquitoborne viral disease in the world, threatens an estimated 
2.5 billion persons in more than 100 endemic countries; 100 million infections occur 
annually. The ongoing risk for dengue is illustrated by endemic disease transmission in 
subtropical areas of the United States (e.g., Puerto Rico); sporadic outbreaks in Florida, 
Texas, and Hawaii; and thousands of ill travelers who acquire dengue in other parts of the 
world. 
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 performed primary and confirmatory diagnostic testing to determine the etiology of 
suspected and previously unknown vectorborne (VB) human infections;
•	 evaluated commercially produced assays and advanced the development of new products and 
approaches for VB diagnostics ― both optimization of existing and next-generation methods 
― and development of novel field-deployable, inexpensive bedside assays;
•	 advanced development and evaluation of innovative, effective tools for better prediction, 
prevention, and control of VB diseases;
•	 developed, successfully tested, and commercially licensed innovative pesticides derived from 
natural products and effective against mosquitoes, ticks, and other vectors that are
increasingly resistant to existing pesticides (this work has been covered in national media and 
received CDC Innovation funding, an intramural seed grant for ideas that address CDC’s 
public health priorities); 
•	 conducted unique investigations on the immunology, molecular biology, and genetic aspects 
of viruses and their hosts and vectors;
•	 provided diagnostic laboratory testing, reference diagnostic services, and training to local, 
state, and international health laboratories in response to outbreaks, characterization of 
unknown specimens, and participation in field studies for VB investigations; 
•	 provided training and proficiency testing for laboratory partners to improve recognition, 
response, and confidence in VB assay results;
•	 developed one of the first candidate vaccines effective against all four species of dengue 
virus; 
•	 responded to dengue outbreaks in multiple Pacific Island nations and in East Africa; 
coordinated response to yellow fever in Uganda; and responded to a deadly tularemia 
outbreak in Louisiana; and 
•	 completed validation and regulatory studies required for FDA 510(k) review of the first 





























BUDGET ACTIVITY — EMERGING AND ZOONOTIC INFECTIOUS DISEASES: 
LYME DISEASE 
CDC addresses the growing public health threat in the United States posed by Borrelia 
burgdorferi, the pathogen that is transmitted by Ixodes ticks that cause Lyme disease (LD). LD
was the sixth highest incident reportable disease in the United States in 2010, with 30,158 cases 
reported to CDC. Since becoming nationally notifiable in 1991, LD has been increasing steadily
in the United States, both in case numbers and in geographic distribution.
Laboratory activities support CDC’s four-part strategy for LD prevention: (1) strengthen and 
refine national surveillance; (2) identify and validate effective prevention methods and 
approaches; (3) improve early and accurate diagnosis and treatment; and (4) leverage
collaborative potential with external partners and stakeholders.
To combat this growing public health problem, CDC laboratories work to develop new 
prevention tools for persons and communities, better diagnostic tests to reduce misdiagnosis, and 
new vaccine candidates to replace the former LD vaccine for which production was discontinued 
in 2002. 
Selected Laboratory Activities in FY2011
CDC laboratories
•	 provided diagnostic and reference services for LD;
•	 developed a comprehensive LD serum panel for validation and use in FDA licensing of new 
diagnostic tests;
•	 distributed reference reagents to internal laboratories and external academic, clinical, and 
pharmaceutical laboratories;
•	 conducted research to test a novel, food-grade insecticide; evaluated a bait box with 
antibiotic bait plus a topical pesticide for mites and ticks targeting rodent reservoirs of LD; 
evaluated an oral, rodent-targeted vaccine; and tested a commercially available doxycycline 
cream as tick-bite prophylaxis; 
•	 discovered a novel LD vaccine target for humans;
•	 furthered development of LD diagnostic tests that are simpler, more objective, more 
sensitive, and accurate in detecting early disease;
•	 identified biomarkers of active LD for potential use in novel diagnostics;
•	 initiated development of new tick diagnostic methods that included genetic tests for studying





























•	 managed a cooperative agreement that funded tests and testing services in 19 state health 
departments in LD endemic and borderline endemic areas;
•	 initiated a study at one TickNet site to define the frequency of southern tick-associated rash 
illness that mimics early LD; and
•	 launched an enhanced communication plan and Internet-based prevention toolkit that 
includes information regarding laboratory testing for LD to improve public awareness and 
knowledge.
BUDGET ACTIVITY — EMERGING AND ZOONOTIC INFECTIOUS DISEASES: 
FOOD SAFETY
Every year in the United States, an estimated 1 in 6 U.S. residents experiences a foodborne
illness, 128,000 are hospitalized, and 3,000 die from foodborne illnesses. The agents responsible 
for these outbreaks include bacteria such as Escherichia coli O157, Salmonella, Shigella, 
Listeria, and Campylobacter; parasites such as Cryptosporidium, Entamoeba histolytica, 
Naegleria fowleri, Angiostrongylus cantonensis, and Plasmodium; and viruses such as norovirus 
and hepatitis A. 
Food recalls help stop foodborne disease outbreaks, thereby preventing additional illnesses, 
hospitalization, and deaths. Preventing a single fatal case of E. coli O157 saves up to $7 million 
in direct medical costs. The CDC Food Safety Program’s laboratory activities support detection, 
control, and prevention of foodborne illness outbreaks.
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 led and coordinated the PulseNet system — a network of public health and food regulatory
agency laboratories that includes 75 laboratories in the United States and 82 countries around 
the world (PulseNet member laboratories perform standardized molecular subtyping or 
fingerprinting of foodborne disease-causing bacteria and submit the results to CDC where the 
information is stored and made available online to other participants involved in foodborne 
disease investigations, upon request, allowing rapid comparison of fingerprints to link cases 
within a single outbreak); 
•	 investigated outbreaks of foodborne illness and provided outbreak assistance by testing
suspected outbreak samples and facilitating outbreak investigations onsite;
•	 led the public health and food safety systems in detecting, investigating, and controlling



























—	 listeriosis outbreak associated with Colorado cantaloupes, which resulted in the deadliest 
foodborne disease outbreak in the United States in approximately 90 years; 
—	 multidrug-resistant Salmonella serotype Heidelberg outbreak associated with ground 
turkey;
—	 salmonellosis outbreak linked to papaya; and
—	 three E. coli O157 outbreaks linked to romaine lettuce, hazelnuts, and bologna;
•	 played a major role in the investigation of the German E. coli O104:H4 outbreak by
confirming U.S. cases and linking international cases; 
•	 coordinated the ongoing laboratory response to the cholera outbreak in Haiti, including
testing of human and environmental samples and the training of Haitians in laboratory
methods; 
•	 led and coordinated CaliciNet — an electronic norovirus outbreak surveillance network that 
allows participants to compare fingerprints from norovirus outbreaks, often occurring on 
cruise ships, that have a common source, allowing for rapid comparison of fingerprints to 
link cases within a single outbreak;
•	 improved capacity at the state and local levels in conducting surveillance for foodborne 
diseases and in detecting, investigating, controlling, and reporting outbreaks;
•	 trained state and local laboratory personnel to assist in foodborne outbreak investigations;
•	 provided surge capacity testing for state health departments lacking the laboratory capacity
crucial for rapid foodborne outbreak investigation and monitoring;
•	 provided worldwide reference laboratory support to address diagnostic testing for hepatitis 
A; 
•	 developed and improved tests to detect and identify foodborne disease-causing agents (e.g., 
Salmonella molecular subtyping and E. coli genotyping test methods); and
•	 provided data and analysis to FDA and USDA on which to base food safety action and policy





























BUDGET ACTIVITY — EMERGING AND ZOONOTIC INFECTIOUS DISEASES: 
CHRONIC FATIGUE SYNDROME 
CFS is estimated to affect 1–4 million U.S. residents. The illness is long-lasting and debilitating,
with a negative effect on health and quality of life similar to heart disease, multiple sclerosis, 
cancer, and AIDS. In the United States, the related annual loss in productivity is worth an 
estimated $9 billion, with additional direct medical costs.
CDC supports an intramural multidisciplinary program that obtains and analyzes baseline 
information that will aid development of interventions for CFS and will improve measurement of 
clinical outcomes. Laboratory activities are directed at improving CFS diagnosis and attempting
to identify groups responsive to specific therapies. These activities complement clinical research
initiatives that focus on the causes, consequences, and treatment of CFS and related diseases.
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 maintained the collection, processing, and archiving of serum, plasma, saliva, whole blood 
DNA, and RNA samples from CDC studies to form a biorepository linked to clinical and 
epidemiologic data for discovery and validation of biomarkers for CFS (materials have 
already been used for collaborative projects involving xenotropic murine leukemia virus-
related virus, metagenomics for unknown pathogens, and for salivary biomarker discovery);
•	 conducted molecular analyses (e.g., gene expression profiling) and evaluated markers of 
inflammation in blood samples from case-control studies of stress-response as an approach to 
understanding the pathophysiology of CFS and to identifying CFS subgroups with targets for 
therapeutic intervention; 
•	 analyzed functional magnetic resonance imaging case-control data to investigate the 
hypothesis that fatigue in CFS correlates with alterations in the brain;
•	 initiated studies to evaluate human herpesvirus-6 in CFS and to identify biomarkers of 
fatigue; and
•	 continued efforts to discover potential biomarkers and the underlying pathophysiology of 
CFS to validate the importance of the illness and to provide an impetus for new therapeutic 
strategies.
BUDGET ACTIVITY — EMERGING AND ZOONOTIC INFECTIOUS DISEASES: 
EMERGING INFECTIOUS DISEASES 
The range of pathogenic organisms and infectious diseases covered by this budget activity is 
broad and includes viral, bacterial, fungal, and parasitic agents. The goals of CDC’s emerging
infectious disease activities are to build state and local public health laboratory capacity






























In addition to these activities, the Emerging Infectious Diseases funding line also provides cross­
cutting laboratory services essential to the operation of all CDC infectious diseases laboratories. 
These laboratories have many functions, including but not limited to 
•	 reference and diagnostic testing, technical assistance, consultation, and training for state, 
local, tribal, and other partners worldwide;
•	 testing in support of numerous surveillance programs;
•	 testing in support of outbreak response investigations;
•	 identification and characterization of novel, unusual or atypical pathogens;
•	 development, evaluation, and deployment of diagnostic tests and reagents;
•	 support for vaccine evaluation trials; and 
•	 provision of proficiency testing programs for other laboratories.
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 provided worldwide reference laboratory support to address
— health care–associated infections, including
investigating and responding to emerging infections, adverse events, and disease 
outbreaks associated with health care delivery in all settings, including health care– 
associated infections, which alone result in approximately 100,000 deaths and cost in 
excess of several billion dollars annually;
improving detection and characterization of health care–associated pathogens (e.g., 
Clostridium difficile and methicillin-resistant Staphylococcus aureus [MRSA]);
detecting novel and emerging antimicrobial resistance in health care-associated 
bacteria; and
studying the importance of health care–associated disease pathogens in biofilms (e.g., 
on medical devices);
—	 high-consequence pathogens, including anthrax, melioidosis, glanders, Ebola and 
Marburg hemorrhagic fevers, rabies, monkeypox, smallpox, and brucellosis, including
using molecular techniques to characterize high-consequence bacteria in clinical 





























serving as WHO Collaborating Centers for viral hemorrhagic fevers, for poxviruses,
and for reference and research on rabies;
serving as an international laboratory of the World Organization for Animal Health, 
providing diagnostic reference testing for human pathogens that are carried by
animals;
identifying and characterizing potential molecular targets for treating and preventing
infections with high-consequence viruses;
expanding the range of diagnostic capacity by improving molecular and serological 
assays to high-consequence viruses; and
providing ongoing training and monitoring of partner nations on laboratory quality
improvement, competency, and staff training in accord with Defense Threat
Reduction Agency guidelines and goals.
—	 respiratory and enteric diseases (e.g., Legionella, Group A and B streptococcus, 
mycoplasma, respiratory syncytial virus, adenovirus, coronaviruses [SARS], and 
rotavirus), including 
o 	 serving as a worldwide reference laboratory and training resource for diagnostic 
testing and antimicrobial susceptibility testing;
o 	 developing new diagnostic tests, including a novel assay that can be used during an 
outbreak to test simultaneously for 21 different respiratory pathogens;
o 	 conducting surveillance studies to determine the burden of respiratory disease in the 
United States; and 
o 	 supporting the global introduction of new vaccines against pneumococcal pneumonia 
and rotavirus (e.g., by providing reference services for measuring protective antibody
responses to vaccination);
— waterborne and environmental pathogens, including
o identifying pathogenic fungi and detecting antifungal resistance;
o 	 responding to disease outbreaks associated with environmental transmission (e.g., 
through drinking water) and using molecular subtyping to match patient and 
environmental isolates;
o 	 developing and implementing environmental microbiology techniques for detecting, 
recovering, and inactivating infectious pathogens; and


























—	 meningitis prevention, including supporting the development and introduction of a new 
meningitis vaccine in African countries that experience meningitis epidemics and leading
development of the second edition of the WHO manual, Laboratory Methods for 
Diagnosis of Meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, 
and Haemophilus influenzae, a global resource for detection, isolation, and 
characterization of invasive bacterial vaccine-preventable disease agents;
—	 viral hepatitis and STDs, including
o 	 diagnostic testing for acute and chronic hepatitis B and C; 
o 	 establishing a pathogen discovery program to investigate non-A–E viral hepatitis; 
o 	 serologic testing for HPV; and 
o 	 evaluation of the impact of HPV vaccination; 
—	 laboratory support for field investigations of Rocky Mountain spotted fever and other 
rickettsial diseases;
•	 provided expertise to strengthen surveillance and applied research programs to improve 
detection and prevention of new and emerging infectious disease threats, including support 
for 
—	 development of pathogen discovery techniques to identify new and emerging lyssaviruses 
(the viruses that cause rabies);
—	 identification of suitable targets for development of medical countermeasures for viral 
hemorrhagic fevers (i.e., high-consequence viruses); 
—	 development of integrated ecologic and epidemiologic studies for monkeypox and other 
orthopoxvirus diseases in the United States and globally, and improved diagnostic 
capabilities for orthopoxvirus disease worldwide (these studies focus on human disease, 
monkeypox disease ecology, and disease transmission dynamics and provide evidence for 
disease control efforts, including the use of vaccine); 
•	 developed and enhanced critical infrastructure at CDC, including 
—	 high-containment laboratories (biosafety level-3 and -4) required for work with known 
high-consequence pathogens (e.g., anthrax, melioidosis, glanders, Ebola and Marburg
hemorrhagic fevers, rabies, and brucellosis), and critical in the rapid identification of 
newly emerging pathogens associated with high-fatality disease outbreaks;
—	 a pathology laboratory unit that provides state-of-the art diagnostic evaluation of tissue 
specimens to help identify previously unrecognized or new infectious diseases (e.g., 


























—	 an environmental microbiology laboratory activity that develops and implements 

diagnostic and disinfection techniques to enhance food and water safety;
 
—	 a field laboratory in Alaska with a diverse portfolio of activities that supports 
surveillance, studies in antimicrobial resistance, vaccine evaluations, outbreak response, 
applied laboratory research, and preparedness activities; and 
—	 a biotechnology core laboratory that performs high-throughput, next-generation 
sequencing of bacterial, viral, and fungal genomes; associated genomic assembly; and 
advanced bioinformatics for infectious, and importantly, outbreak and unknown pathogen 
identification; proteomic analyses of the functions, structures, and interactions of 
proteins, primarily by mass spectrometry and protein sequencing; chemical synthesis of 
complex oligonucleotides and peptides critical for molecular technologies used by CDC 
laboratories and LRN; as well as evaluates and develops new, cutting-edge technologies 
(these functions and the expertise that supports them continue to provide the data and the 
knowledge needed by CDC scientists and physicians rapidly, particularly during
emergencies, to keep the agency at the forefront of public health in an expanding and 
evolving world); 
•	 provided laboratory infrastructure services to all CDC infectious disease laboratories, 
including 
—	 developing an infectious disease laboratory database — a comprehensive and cross­
linked source of information regarding CDC laboratories for stakeholders and leadership 
and to aid in meeting anticipated FDA requirements for laboratory-developed tests; 
—	 supporting uniform information management systems for infectious disease laboratories 
that enhance capacity for tracking, reporting, and analyzing samples received for testing,
surveillance, and outbreak investigations, as well as providing enterprise capacity for 
interoperability (i.e., data sharing) through technologic advances, shared resources, and 
strategic alignment with external partners;
—	 enhancing a quality management system across CDC’s infectious diseases laboratories to 
strengthen regulatory compliance and adherence to quality standards for these 
laboratories;
—	 supporting cutting-edge public health bioinformatics through a new centralized 
bioinformatics core consisting of highly skilled bioinformatics scientists who collaborate 
with CDC program scientists to facilitate faster pathogen identification, development of 
better diagnostics, and improved analysis of laboratory data for epidemiologic 
surveillance and outbreak investigations; 
—	 purchasing and distributing laboratory supplies and personal protective equipment;




























—	 providing animal care services (maintained at multiple laboratory sites), with ongoing
veterinary care, guidance, and oversight to ensure the welfare of laboratory animals
(unique services that include maintenance of insect and tick colonies for work with VB
pathogens [e.g., dengue and LD]);
—	 managing specimens (including triage, processing, and distribution) and maintaining a 
serum bank used in studies of different pathogens;
—	 decontaminating biologic waste, monitoring autoclaves, and maintaining laboratory water 
systems; and
—	 providing the Laboratory Outreach Communication System for CDC's Emergency
Operations Center and urgent communications during response events to public health 
laboratories and the 25 largest associations for laboratory professionals.
BUDGET ACTIVITY — EMERGING AND ZOONOTIC INFECTIOUS DISEASES: 
OTHER
This budget activity provides funding for activities related to controlling and preventing AR and 
for detecting and controlling diseases for recognized and emerging high-consequence threats 
known as special pathogens. 
Antimicrobial Resistance
AR is one of the world’s most pressing public health threats and is increasing in scope. 
Infections with resistant bacteria have become more common in health care and community
settings. Patients infected with drug-resistant microbes are more likely to require hospitalization, 
remain in the hospital longer, and have a poor prognosis. In a 2008 study of hospital-acquired 
antimicrobial-resistant infections, the medical costs attributable to AR ranged from $18,588 to 
$29,069 per patient; hospital stays were extended by 6.4–12.7 days; and the mortality attributable 
to AR was 6.5%. Using the most conservative estimates, the total cost of the resistant infections 
was $13.35 million dollars for the 188 patients in that study alone.
In efforts to identify, control, and prevent new AR, CDC laboratories set an ultimate standard for 
laboratory testing for state health departments and hospital laboratories, CDC surveillance and 
outbreak control, and analysis of AR transmission and risk factors.
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 provided gold-standard testing services to state health departments, clinical diagnostic 




























•	 supported CDC surveillance systems by testing organisms of public health importance, 
including Streptococcus pneumoniae, Group A and B streptococcus, Neisseria meningitidis, 
MRSA, Haemophilus influenzae, Neisseria gonorrhoeae, Helicobacter pylori, and Candida; 
•	 monitored resistance rates and informed, guided, and evaluated prevention efforts; 
•	 provided outbreak response and technical assistance to state health departments (e.g., 
collaborated with seven state health departments and Puerto Rico to stop outbreaks of 
carbapenem-resistant Enterobacteriaceae, and also provided susceptibility testing for state 
and hospital laboratories);
•	 tested more than 5,000 samples of microbes, including Salmonella, Shigella, Campylobacter, 




•	 conducted strain typing and additional molecular characterization of multiple AR pathogens, 
including carbapenem-resistant Enterobacteriaceae, MRSA, C. difficile, and multidrug­
resistant Acinetobacter species;
•	 detected emergence of antibiotic resistant N. gonorrhoeae and developed molecular assays
for detecting cephalosporin-resistant N. gonorrhoeae in the United States; 
•	 used culture and molecular techniques to detect and identify mechanisms of AR for all 
respiratory and vaccine-preventable bacterial diseases, including S. pneumoniae, N. 
meningitidis, and Group A and B streptococci; 
•	 developed new assays for surveillance of resistant hepatitis C strains by predicting resistance 
to combined interferon/ribavirin therapy among patients chronically infected with hepatitis C 
virus; and 
•	 detected the emergence of a strain of antibiotic-resistant pneumococcus not covered by the 
PCV7 pneumococcal vaccine that was recommended by the Advisory Committee on 
Immunization Practices (ACIP) in 2000 (this helped guide the inclusion of this strain in the 
new pneumococcal vaccine, PCV13, which was recommended by ACIP in 2010). 
Hantavirus/Special Pathogens
Hantavirus pulmonary syndrome is a severe, sometimes fatal, respiratory disease among humans 
caused by infection with a hantavirus. CDC provides continuing surveillance and epidemiologic 
studies of hantaviruses in the United States and globally. CDC also provides reagents, technical 
advice, response teams, and epidemiologic investigations to improve diagnostic and reagent 
capability for hantaviruses and related hemorrhagic fever viruses. Through its laboratory work, 
CDC has developed more sensitive assays for detection of hantaviruses and emerging
hemorrhagic fever viruses, and for evidence of their infection among humans and animal hosts, 






























Selected Laboratory Activities in FY 2011
CDC laboratories
•	 provided laboratory support to all state health departments for hantavirus pulmonary
syndrome diagnostics and consultations regarding case management and surveillance;
•	 provided consultations on hantavirus small animal reservoir populations in North and South 
America;
•	 conducted basic research to understand further the natural history and pathogenicity of 
hantaviruses for improved diagnostics and vaccine development;
•	 completed successful vaccine trials of a live-attenuated Rift Valley fever recombinant virus 
for use among livestock; and
•	 discovered a novel phlebovirus associated with two Missouri cases of severe febrile illness 
with thrombocytopenia.
BUDGET ACTIVITY — CHRONIC DISEASE PREVENTION AND HEALTH 
PROMOTION
Chronic diseases are the leading cause of preventable death in the United States. Prevention and 
control of chronic diseases are among CDC’s highest priorities. Annually, U.S. residents suffer 
more than 2 million heart attacks and strokes. An estimated 443,000 persons die prematurely
from smoking or exposure to secondhand smoke. Cigarette smoking accounts for more than $96 
billion a year in health care–related costs and $97 billion a year in lost productivity. Deficiencies 
in micronutrients (e.g., iron, iodine, vitamin A, folate, and zinc) affect a third of the world's
population. 
CDC’s related laboratory activities center on developing and applying accurate, high-quality
methods to (1) improve detection, diagnosis, treatment, and prevention of cardiovascular disease;
(2) reduce individual and population exposure to addictive and toxic substances in tobacco 
products; and (3) improve nutrition through reductions in micronutrient deficiencies.
Selected Laboratory Activities in FY 2011
Lipid Standardization Program and Reference Lipid Testing
CDC laboratories
•	 developed and maintained highly accurate and precise methods, including two new mass 
spectrometry reference methods, to measure total cholesterol, high-density lipoprotein (HDL) 






















• operated an internationally recognized reference laboratory to calibrate and monitor 
accurately, over time, cholesterol and lipid measurements used in patient care, public health, 
and research;
•	 served as the only U.S. laboratory that provides technical assistance on cholesterol and lipid 
assessment through reference measurements, training, and professional education activities; 
•	 conducted research to identify and better address problems with current cholesterol and lipid 
measurements;
•	 provided quality-control materials to 84 laboratories, including 43 research (academic) 
laboratories, 38 commercial laboratories performing patient-care testing and clinical trials, 
and three assay manufacturers to ensure accuracy of lipid measurement for ongoing U.S. and 
international studies of cardiovascular disease; and 
•	 assigned reference values to proficiency testing survey materials used in assessing the 
performance of patient care, public health, and research tests (in collaboration with the 
College of American Pathologists).
Tobacco Testing 
CDC laboratories
•	 maintained the only federal laboratory that measures addictive and toxic substances in 
tobacco products and smoke, as well as in the urine and blood of persons who use tobacco or
are exposed to secondhand smoke; 
•	 studied the effects of chemical additives, constituents, and design on the toxicity and 
addictiveness of tobacco products; 
•	 documented the impact that different types of cigarettes and smoking styles have on exposure
to carcinogenic tobacco-specific nitrosamines (TSNAs) and used these laboratory findings to 
shape future CDC NHANES surveys, which will track cigarette types and smoking behaviors 
to monitor how changes in cigarette composition affect human exposure (see the Public 
Health Scientific Services section for a more detailed description of NHANES); 
•	 assessed U.S. residents’ exposure to the harmful chemical constituents of tobacco smoke, 
including measuring a highly specific biomarker of the most carcinogenic TSNA (the first 
assessment of exposure to tobacco carcinogens among the U.S. population) and serum 
cotinine, a marker of nicotine and secondhand smoke exposure, thereby determining that 
nonsmokers’ exposure to tobacco carcinogens increases with their exposure to secondhand 
smoke; 
•	 collaborated in health studies examining the association of secondhand smoke exposure with 

























•	 demonstrated that roll-your-own cigarettes deliver as much as or more mainstream smoke as 
manufactured cigarettes, potentially increasing a smoker’s exposure to toxic and addictive 
chemicals;
•	 collaborated with FDA’s southeastern regional laboratory to establish standard methods to 
measure tobacco product constituents and to enhance FDA laboratories’ capability to conduct 
tests in support of regulatory standards; and
•	 supported global laboratory capacity to analyze addictive and toxic substances in tobacco 
through shared development of testing methods and test validation (in collaboration with the 
World Health Organization’s Tobacco Laboratory Network).
Quality Assurance and Training for Micronutrient Testing
CDC laboratories
•	 improved laboratory measurements to detect micronutrient deficiencies so that national 
nutrition surveys in developing countries can efficiently and reliably assess nutritional status; 
and 
•	 provided full laboratory support, including technical assistance, in-country planning and 
training, external quality assessment, and technology transfer to ensure accurate assessment 
of nutritional status in national nutrition surveys in the Democratic Republic of Congo, the 
Dominican Republic, Iraq, Kenya, Kyrgyzstan, and Malawi.
BUDGET ACTIVITY — BIRTH DEFECTS, DEVELOPMENTAL DISABILITIES, 
DISABILITY, AND HEALTH 
Birth defects and blood disorders place a considerable burden on persons, families, and society. 
Approximately 1 in 33 babies (or about 130,000 annually) is born with a birth defect. Birth 
defects account for more than 20% of infant deaths and result in more than $2.6 billion annually
in hospital costs. Nonmalignant blood disorders affect millions of U.S. residents each year. 
Direct health care costs for hemophilia alone exceed $1 billion per year and might approach $3– 
$4 billion if complications are considered.
CDC’s internal laboratory activities to address birth defects and blood disorders focus on (1)
preventing and reducing the adverse consequences of birth defects by conducting studies to 
identify genetic factors that contribute to the causes of these complex diseases and (2) preventing





























Selected Laboratory Activities in FY 2011
CDC laboratories
•	 served as the central laboratory for the National Birth Defects Prevention Study (NBDPS), 
the largest population-based case-control study in the United States that collects genetic 
samples and information regarding environmental exposures; in collaboration with eight 
grantees,
—	 tested the quality of more than 5,500 biologic specimens collected at NBDPS sites;
—	 developed, validated, and performed genetic tests for research studies on selected birth 
defects;
—	 investigated and applied optimal methods for DNA collection, processing, and quality
assessment and provided guidance on the long-term storage of biologic specimens; 
—	 provided quality-assurance materials and technical assistance to ensure that collaborating
NBDPS laboratories perform highly accurate measurements; 
—	 performed pilot projects to evaluate new technologies for the collection, processing, 
genotyping, and storage of biologic specimens; and 
—	 evaluated collection methods and provided guidance to increase the effectiveness of 
NBDPS sample use;
•	 monitored for infectious agents in the U.S. blood supply to prevent the transmission of 
infectious diseases to persons undergoing treatment for bleeding disorders and thalassemia 
(the only laboratory in the world that conducts such active infectious disease surveillance);
•	 monitored and adapted new technologies for surveillance of blood products;
•	 performed genetic and other related research on coagulation inhibitor (antibody) formation, a 
serious complication among hemophilia patients;
•	 compiled and maintained a national database of genetic information to help providers 
diagnose and prevent disease complications associated with hemophilia and coagulation 
inhibitors;
•	 maintained the largest collection in the world of DNA samples from persons of African 
descent in the United States who have had a venous thrombosis event (a critical resource for 
defining risk factors among this population); and
•	 performed ABO Blood Group type testing during the 2011 Haiti cholera outbreak to assess 


















BUDGET ACTIVITY — ENVIRONMENTAL HEALTH 
Public health action to protect the nation’s health includes promoting a healthy environment and 
preventing premature death, avoidable illness, and disability caused by noninfectious, 
nonoccupational, environmental, and related factors. CDC’s Environmental Health Laboratory
provides unique laboratory science to improve detection, diagnosis, treatment, and prevention of 
(1) diseases that result from exposure to environmental chemicals, (2) treatable congenital 
disorders among newborns, and (3) nutrition-related diseases and selected other diseases 
requiring advanced laboratory measurement for accurate diagnosis.
Environmental Health Laboratory
Selected Laboratory Activities in FY 2011
Biomonitoring of Chemical Exposures
In the United States and internationally, persons come into contact with thousands of chemical 
substances in the environment, both naturally occurring and manufactured. The Environmental 
Health Laboratory conducts biomonitoring — the direct measurement of environmental 
chemicals, or their products, in human blood and urine — to assess population and individual 
exposure to environmental chemicals.
CDC laboratories
•	  conducted the nation’s only comprehensive assessment of U.S. residents’ exposure to more 
than 300 chemicals in the environment through biomonitoring of persons who participate in 
the ongoing NHANES survey (see the Public Health Scientific Services section for a more 
detailed description of NHANES); 
•	 updated the Fourth National Report on Human Exposure to Environmental Chemicals to 
include new biomonitoring results for 66 environmental chemicals, including cotinine, 
bisphenol-A, phthalates, triclosan, and perfluorchemicals;
•	 provided laboratory measurements for 50 studies that examined the exposure of vulnerable 
groups to environmental chemicals or investigated associations between exposures and 
adverse health effects;
•	  served as the world’s sole or primary source for high-quality laboratory tests in human blood 
or urine for bisphenol-A, trans fatty acids, speciated arsenic, uranium, speciated mercury, 
volatile organic compounds, phthalates, triclosan, selected radionuclides (e.g., polonium-210, 







   
 
   
 













•	 developed, evaluated, and applied innovative laboratory methods to
—	 improve response to public health emergencies, including emergencies that involve 
disease and death from unknown causes; and
—	 measure and analyze priority environmental chemicals;
•	 provided technical support, training, quality assurance, and technology transfer to state and 
local laboratories during investigations of known and potentially unsafe chemical exposures;
and 
•	 demonstrated the impact of voluntary discontinuation of the use of perfluorooctane sulfonic 
acid (PFOS) by documenting a substantial reduction in human exposure to PFOS after the 
end of production in 2002. 
Newborn Screening 
Each year, more than 4 million newborns ― nearly every newborn ― in the United States are 
screened for such disorders as congenital hypothyroidism and sickle cell disease. These 
conditions often can be treated to prevent serious complications if detected early in life. State 
public health laboratories — which test 98% of U.S. infants for birth defects every year — rely
on CDC to ensure the accuracy of testing and to develop methods for detecting congenital 
disorders that are not apparent at birth.
CDC laboratories
•  operated the nation’s only quality-assurance program to ensure the accuracy of newborn 
screening tests to detect treatable diseases that cause malformation, mental retardation, and 
death;
•	 provided newborn screening quality-assurance materials, proficiency testing, and technical 
assistance to more than 500 laboratories in all 50 U.S. states and in 67 countries;
•	 developed new methods to detect newborn diseases; and 
•	 conducted laboratory studies that supported the addition of severe combined 
immunodeficiency (SCID), better known as “Bubble Boy Disease,” to the U.S. Department 
of Health and Human Services Secretary’s Recommended Uniform Newborn Screening
Panel ― the first new condition added to the original panel of 29 conditions (SCID affects an 























   
 
  
Nutrition-Related and Selected Other Chronic Diseases
Prevention and treatment of nutrition-related and selected other chronic diseases require accurate 
laboratory measurement to detect and diagnose disease and to assess the effectiveness public 
health interventions.
CDC laboratories
•	  conducted the nation’s only comprehensive assessment of the nutritional status of the U.S. 
population by measuring more than 50 nutritional indicators among persons who participate 
in NHANES (see the Public Health Scientific Services section for a more detailed description 
of NHANES);
•	 developed new and improved methods for measuring nutritional and dietary bioactive 
compounds, including a method to monitor vitamin D blood levels among populations; and 
•	 standardized and improved the accuracy of clinical measurements for cholesterol, related 
lipids, testosterone, estradiol, and selected other diagnostic tests for chronic diseases.
Healthy Homes/Childhood Lead Poisoning 
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 conducted the nation’s only comprehensive assessment of U.S. residents’ exposure to lead 
through biomonitoring of persons who participate in the NHANES survey, determined the 
prevalence of persons (including children aged 1 year and older) with lead exposures higher 
than toxicity levels, and reported elevated exposures to ensure effective treatment and 
exposure interventions (see the Public Health Scientific Services section for a more detailed 
description of NHANES);
•	 provided laboratory measurements for 11 studies (including the National Children’s Study)
that examined the exposure of vulnerable groups to lead;
•	 provided blood lead quality assurance to nearly 70 U.S. laboratories through CDC’s Lead 
and Multi-Element Proficiency Program;
•	 provided portable blood lead instruments, quality assurance, training, and laboratory
assistance to the investigation of an outbreak of lead poisoning in two mining villages in 
Nigeria, where CDC staff used the portable lead instrument to identify exposed children 



























BUDGET ACTIVITY — PUBLIC HEALTH SCIENTIFIC SERVICES 
This budget activity provides funding for activities related to support services for CDC’s 
laboratories and for selected laboratory testing as part of CDC’s unique NHANES survey.
Laboratory Support Services
The success of CDC’s laboratory scientists and laboratories depends on their access to a 
spectrum of scientific, technical, policy, and other services provided by multiple CDC offices. 
These essential support services extend from coordination of national CDC laboratory initiatives 
to assistance in complying with multiple federal regulatory mandates. They also include 
technical training, laboratory worker safety, and availability of suitable equipment and facilities, 
among other services.
Selected Laboratory Activities in FY 2011
CDC laboratory-support services
•	 assessed implications for the agency’s laboratories if state and local public health laboratories
— the majority of which operate under intense fiscal and other pressures — continue to lose 
capacity to conduct critically important tests (this led to creation of the new Laboratory
Efficiencies Initiative to help them maintain testing capacity and achieve long-term 
sustainability through the adoption of alternative high-efficiency management practices);
•	 provided consultation to CDC laboratory directors regarding compliance with federal 
regulatory requirements related to disease agents that have potential to pose severe threats to 
human, animal, and plant health and to animal and plant products; 
•	 coordinated formulation and implementation of a uniform, agencywide policy to assist CDC 
laboratories in complying with the federal Select Agents and Toxins regulations (the 
regulations are available at http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&tpl=/
ecfrbrowse/Title42/42cfr73_main_02.tpl); 
•	  enhanced management of CDC’s central collection of more than 6 million biologic 
specimens and delivered more than 700,000 specimens to CDC and extramural scientists for 
research into the causes and prevention of disease;
•	 trained more than 450 CDC scientists in dual-use research awareness and policies (based on 
recommendations of the National Science Advisory Board for Biosecurity) to prevent release 
of research findings that can be misused intentionally to pose a biologic or chemical threat to 
public health or national security;
•	 provided advanced training through the National Laboratory Training Network to state and 
local public health laboratory professionals, preparing them to respond to biologic and 



























•	 provided training in safe handling practices and in specialized microbiology testing for BT
agents;
•	  managed CDC’s technology transfer program to facilitate commercialization of inventions 
generated by CDC laboratory scientists and other researchers;
•	 licensed 51 inventions by CDC laboratory scientists for production and sale by private-sector 
firms and maintained an additional 1,116 patents based on CDC inventions consistent with 
U.S. Patent and Trademark Office requirements;
•	  managed CDC’s cooperative agreement with the Association of Public Health Laboratories 
to assist CDC’s scientists in conducting research, developing informatics applications, 
delivering training, and implementing other high-priority projects with extramural partners; 
and 
•	 supported agencywide plans to review and comply with FDA regulatory requirements for in 
vitro diagnostic devices.
The National Health and Nutrition Examination Survey
Data from NHANES have been the cornerstone for national health and nutrition policy and 
surveillance activities — the surveys are the only collection of biologic samples related to 
nutrition and health on a populationwide basis in the United States. Each year, tens of thousands 
of specimens from NHANES participants are processed and shipped to multiple CDC programs 
for laboratory analysis of nutritional biochemistries, environmental exposures, infectious 
diseases, and other health indicators. Approximately 250 different types of laboratory tests are 
performed. Those CDC programs provide funding for the laboratory tests they need, with the 
following exception, which is supported by the Public Health Scientific Services funding line.
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 received, processed, and tested more than 4,500 blood samples for a complete blood count, a 
panel of tests used to screen for such disorders as anemia, presence of infection, and other 
diseases.
BUDGET ACTIVITY — OCCUPATIONAL SAFETY AND HEALTH
Workers typically spend a quarter of their lives and up to half of their waking hours at work, 
making the workplace a key location for health problems. During 2010, employers in the private 
sector reported approximately 2.9 million nonfatal work-related injuries and approximately
200,000 cases of occupational illness. On average, 14 workers in the United States die each day
from an injury sustained at work (approximately 4,500 workers during 2010), and another 134 



























diseases and injuries are approximately $250 billion. CDC maintains unique laboratory capacity
for conducting multidisciplinary occupational safety and health research and provides global 
leadership in areas of evidence-based information to prevent work-related illness, injury,
disability, and death.
Selected Laboratory Activities in FY 2011
Assessment of Mining Health and Safety Hazards and Disaster Prevention 
CDC laboratories
•	 conducted full-scale experiments before testing interventions at working mine sites; 
•	 developed a new award-winning LED cap lamp to prevent injuries by enhancing the 
illumination of underground mines and associated hazards, including uneven and cluttered 
surfaces, areas of unstable rock, and other obstacles integral to mining operations; 
•	 improved understanding of mine explosions, designed explosion and fire suppression 
strategies, and developed approaches for minimizing or preventing massive rock failures by
using the unique capabilities of the Lake Lynn Laboratory and the Mine Roof Simulator; 
•	 simulated underground coal mining conditions at active production zones and conducted 
research that addresses health hazards (e.g., coal dust); 
•	 identified inadequate coal mine dusting standards, which led the U.S. Department of Labor to 
issue an Emergency Temporary Standard for all coal mines to prevent coal dust explosions; 
and 
•	 conducted research on hearing loss prevention for mine workers using large-scale mining
equipment. 
Improved Personal Protective Equipment and Technologies
CDC laboratories
•	 conducted research to advance technology to improve protection, comfort, fit, and the use of 
personal protective equipment and to examine exposures to inhalation, dermal, and other 
occupational hazards;
•	 conducted firefighter turnout gear investigations and research in personal protective 
equipment anthropometrics and aerosols/filtration by using capabilities that exist in only a 
few laboratories in the world (e.g., human metabolic response simulation and chemical 
protective clothing penetration); 
•	 administered the respirator certification program to ensure a level of standard filter efficiency
for all respirators used in U.S. workplaces by using the only full-size respirator testing





























•	 improved the quality and quantity of respiratory protection for workers through 588 certified 




•	 developed and evaluated methods used worldwide to sample and analyze contaminants in 
workplace air and in the blood and urine of workers who are exposed occupationally;
•	 designed and tested aerosol sampling equipment prototypes to evaluate exposure to ultrafine 
and nanoparticles in field studies; 
•	 identified, evaluated, developed, and implemented technology to prevent worker exposure to 
workplace health hazards; and 
•	 developed a portable, free-standing airborne isolation system capable of producing airborne 
infection isolation in harsh environments.
Applied Toxicology
CDC laboratories
•	 used diverse laboratory disciplines (e.g., exposure generation and assessment, pulmonary
toxicology, cardiovascular toxicology, and neurotoxicology) to answer critical questions 
about workplace hazards and how they affect workers on a biologic and physiological level;
•	 conducted aerosol generation and animal inhalation exposure research for work-related 
hazards (e.g., multiwalled carbon nanotubes, carbon nanofibers, welding fumes, and artificial 
flavorings);
•	 conducted research by using animal models and published a series of reports on the health 
effects of the oil dispersant used in the Deepwater Horizon emergency response; 
•	 used a biosafety level-3 adaptable laboratory with simulated patient examination room 
complete with a coughing and breathing mannequin to monitor health care workers’ potential 
aerosol exposure to an infected patient; and
•	 demonstrated aerosolized transmission of influenza virus in laboratory studies and hospital 
settings and characterized viral particle size and quantity in coughs from influenza patients.
Safety Engineering 
CDC laboratories


































•	 researched human behavior, physical responses, and decision-making skills under simulated 
conditions of work at elevated heights by using unique virtual reality capacity;
•	 researched interactive effects of biomechanics, physiological load, and psychological stress 
on workers; and
•	 registered and quantified human body size and shape of various occupational groups for use 
in developing improved equipment designs (e.g., developed and disseminated a
comprehensive database of truck driver anthropometrics to major truck manufacturers who 
are using the data to improve truck cab design for increased safety).
BUDGET ACTIVITY — GLOBAL HEALTH: GLOBAL AIDS PROGRAM
Thirty years since the onset of the HIV/AIDS epidemic, technical advances and improved 
knowledge of disease epidemiology have led to investments in prevention and treatment that are
helping to reduce new infections, save lives, and achieve an AIDS-free generation.
U.S.-based CDC laboratories provide technical assistance and expert consultation to advance the 
U.S. Global Health Initiative and the President’s Emergency Plan for AIDS Relief (PEPFAR) by
improving disease prevention and treatment and care for persons living with HIV/AIDS.
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 served as worldwide reference laboratories for diagnosis and drug-resistance testing for 
HIV/AIDS, providing services to both domestic and international partners (see the Domestic 
HIV/AIDS section for additional activities); 
•	 provided laboratory support to address public health priorities in HIV diagnosis, prevention, 
care, and treatment, as well as in cross-cutting areas (e.g., HIV/TB co-infection, health 
systems strengthening, public health training, and laboratory biosafety and biosecurity);
•	 helped developing countries’ laboratories implement improved methods for diagnosis of HIV 
and AIDS-related opportunistic infections, including co-infection with TB; for HIV and TB
drug-resistance testing; for measurement of blood CD4+ levels and HIV viral loads to 
monitor disease progression and treatment effectiveness; and for HIV incidence testing to 
monitor the effect of disease prevention and control efforts;
•	 assisted ministries of health in 45 countries in developing national laboratory strategic plans 
that strengthen the laboratory component of national health systems (e.g., by implementing
quality laboratory services and systems, strengthening laboratory biosafety and biosecurity, 





























•	 provided support for hands-on training to 865 laboratory professionals in 283 laboratories in 
22 countries to improve accreditation preparedness, and helped to establish the African 
Society for Laboratory Medicine, which will administer a regional laboratory accreditation 
program;
•	 strengthened HIV/AIDS prevention and control programs by
—	 providing support for training and diagnostic assistance to developing country public 
health laboratories that collectively tested 9.8 million pregnant women for HIV, leading
to prevention of mother-to-child transmission and allowing an estimated 200,000 infants 
to be born HIV-free;
—	 providing testing panels to 120 laboratories in 40 PEPFAR countries to facilitate training
in drug-resistance testing by using the low-cost dried blood spot assay developed at CDC;
and 
—	 evaluating the quality of HIV rapid tests considered for inclusion in the USAID waiver 
list, which authorizes local procurement of goods and services under PEPFAR (use of 
these rapid tests allows prompt referral for care and treatment); and
•	 conducted operational research to
—	 evaluate field use of rapid point-of-care tests in resource-limited settings (e.g., to 

accelerate the entry into care of HIV-positive pregnant women);
 
—	 implement widespread use of molecular tests for early diagnosis of HIV among infants 
(e.g., to allow early determination of the HIV status of infants born to HIV-positive 
mothers); and
—	 scale up collection and analysis of laboratory data for measuring the impact of HIV 
prevention efforts, facilitating faster translation of research findings into local practice.
BUDGET ACTIVITY — GLOBAL HEALTH: GLOBAL IMMUNIZATION PROGRAM
Vaccination against serious infectious diseases (e.g., polio and measles) is one of the most 
effective of all global public health interventions. Globally, cases of polio have decreased by
over 99% since 1988. Polio vaccination in the United States has yielded net economic benefits 
that exceed $180 billion, not counting the intangible benefits associated with eliminating
endemic polio in the United States. Globally, measles deaths declined by 78% during 2000– 
2008, although the disease continues to affect more than 20 million persons each year. Measles 
vaccination is one of the most cost-effective health interventions available today for preventing
deaths. 
However, much remains to be done. U.S.-based CDC laboratories are helping to advance the 
Global Polio Eradication Initiative by providing critical diagnostic services and genomic 




























   
disease control efforts in multiple countries. The CDC Polio Laboratory serves as a WHO global 
specialized laboratory, a high-level facility that provides technical and programmatic assistance 
to the Global Polio Laboratory Network. CDC also is helping to advance the Global Measles 
Initiative, which aims to accelerate the reduction of measles deaths worldwide. Moreover, 
increased use of a combined measles and rubella vaccine is also reducing birth defects caused by
congenital rubella syndrome. The CDC measles and rubella laboratories are WHO global 
specialized laboratories within the WHO Measles and Rubella Laboratory Network.
In addition, CDC laboratories support global efforts to prevent children’s deaths from other 
vaccine-preventable diseases by increasing access to vaccines in low-resource countries and by
helping to strengthen surveillance capacity.
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 served as worldwide reference laboratories ― and as regional reference laboratories for the 
Pan American Health Organization ― for diagnosis of polio, measles, and rubella, as well as 
for other vaccine-preventable diseases (i.e., infections with Streptococcus pneumoniae, 
Haemophilus influenza type b, Neisseria meningitidis, and pertussis); 
•	 provided proficiency testing, technical assistance, and training and consultation regarding
best practices to expand and enhance the WHO Global Polio Laboratory Network (145 
laboratories) and the WHO Global Measles and Rubella Laboratory Network (700 
laboratories);
•	 developed, evaluated, and deployed state-of-the art tests for diagnosis, genotyping, and 
subtyping of polio, measles, and rubella; these tests support outbreak investigations and 
disease-tracking and guide polio and measles prevention strategies; 
•	 used global genotyping data to track and contain over 200 domestic cases of measles;
•	 conducted applied research to develop, evaluate, and implement new prevention approaches 
(including vaccines) and treatments (including antiviral drugs) (e.g., the CDC Polio 
Laboratory has evaluated new inactivated polio vaccines, oral polio vaccines, and novel 
vaccine delivery technologies); 
•	 developed and validated disease surveillance tools, including 
—	 a global measles DNA sequence database, developed in collaboration with WHO, that 
provides critical information for controlling measles at home and abroad; and 
—	 a molecular diagnostic assay for poliovirus that will help guide decision-making and 
outbreak response in countries where polio has not yet been eliminated.
•	 provided support for hands-on laboratory training and assistance, including developing and 
publishing laboratory guidelines, for the WHO Invasive Bacterial/Vaccine-Preventable 


























•	 provided support for hands-on laboratory training and sentinel site assistance to ministries of 
health in three central African countries (Cameroon, Central African Republic, and the 
Democratic Republic of Congo) for laboratory-based surveillance of vaccine-preventable 
diseases as part of the Projet de Renforcement de la Surveillance en Afrique Centrale project.
BUDGET ACTIVITY — GLOBAL HEALTH: GLOBAL DISEASE DETECTION AND 
EMERGENCY RESPONSE
CDC’s U.S.-based infectious disease laboratories support the overseas laboratory operations of 
the CDC Global Disease Detection (GDD) regional centers whose goal is to strengthen global 
health security by ensuring (1) prompt identification and reporting of new threats and (2) rapid 
response to public health threats, including public health emergencies of international concern 
reported to WHO under the International Health Regulations (IHR).
The GDD Regional Centers ― located in China, Egypt, Guatemala, India, Kenya, Thailand, and 
South Africa ― work closely with U.S.-based CDC laboratories and with the GDD Operations 
Center in Atlanta.
Selected Laboratory Activities in FY 2011
The U.S.-based CDC infectious disease laboratories provided guidance, technical support, and 
management services to GDD regional centers that 
•	 served as regional resources for
—	 technical assistance, training, and rapid coordination of diagnostic testing during public 
health emergencies; and
—	 strategic planning for IHR implementation;
•	 detected seven pathogens that were new to the world, new to their geographic region, or for 
which testing capacity now exists (e.g., a Bartonella vinsonii subspecies, Streptococcus 
difficilis, metapneumovirus, and a Crimean-Congo hemorrhagic fever variant); 
•	 worked with ministries of health in China, Guatemala, Kenya, and Thailand to strengthen 
national public health laboratory systems that optimize the use of local resources;
•	 worked with the ministries of health of China and Thailand to advance IHR implementation 
by developing and customizing laboratory system assessment tools for IHR compliance and 
conducting assessments in 29 laboratories in Guangdong Province, China, and 13 regional 
medical centers and clinical laboratories in Thailand; 
•	 advanced development of the WHO Laboratory Quality Management System and distributed 
the system handbook, which is based on training sessions and modules provided by CDC and 























   
 
  
•	 disseminated two diagnostic tests to laboratories in GDD host countries, including a real-time 
diagnostic platform for use in identifying causes of unexplained respiratory disease 
outbreaks.
BUDGET ACTIVITY — GLOBAL HEALTH: PARASITIC DISEASES AND MALARIA
Parasitic infections are responsible for a major disease burden throughout the world. Malaria 
affects 250–300 million persons annually, resulting in approximately 700,000 deaths, primarily
among children. Approximately 1,500 cases of malaria are diagnosed each year in the United 
States, primarily from returning travelers and immigrants. Other parasitic diseases — sometimes 
called “neglected tropical diseases” — affect more than 1 billion persons, including certain 
diseases that are endemic to the United States (e.g., neurocysticercosis, toxocariasis, and 
toxoplasmosis). 
The U.S.-based CDC infectious disease laboratories focus on advancing the U.S. Global Health 
Initiative, the President’s Malaria Initiative, and the Neglected Tropical Diseases Initiative and 
on improving diagnosis and control of parasitic diseases in the United States. 
Selected Laboratory Activities in FY 2011
CDC laboratories
•	 served as a worldwide reference center for
—	 diagnosis of malaria, neglected tropical diseases, and other parasitic diseases; and 
—	 evaluation of commercially available rapid diagnostic tests for malaria;
•	 provided assistance, training, and consultation to state and local public health departments in
diagnosing, investigating, preventing, and controlling parasitic diseases; and 
•	 provided first-line and reference diagnostic testing services for physicians, hospitals, clinical 
laboratories, and government partners;
•	 conducted over 15,000 diagnostic tests, including microscopic evaluation for over 100 
medically important parasites, immunodiagnostic testing for 14 diseases, and molecular 
detection for over 20 agents;
•	 operated an Internet-based telediagnostic service for parasitic diseases;
•	 developed molecular assays for use in malaria case management and surveillance, as well as 
new methods for diagnosis of other parasitic diseases, including filariasis, cyclosporiasis, 

























    
•	 improved neglected tropical disease diagnoses through validation of laboratory tests, 
including rapid tests and assays to detect multiple diseases from a single drop of blood; 
•	 provided training and consultation to domestic and global partners on surveillance for drug
resistance (e.g., CDC offered training to investigators in endemic countries regarding use of 
molecular markers to detect and track drug-resistant parasites);
•	  provided technical support to ministries of health and WHO ― thus helping to strengthen 
malaria prevention and control programs ― by providing a resident advisor to assist with 
implementing the President’s Malaria Initiative in 15 African countries; and
•	 conducted applied research on antimalarial drugs and on drug resistance mechanisms in 
parasite and vector populations.
BUDGET ACTIVITY — PUBLIC HEALTH PREPAREDNESS AND RESPONSE
CDC’s laboratories are critically important to America’s national security. CDC helps the nation 
prepare for and respond to urgent public health threats by providing strategic direction, support, 
and coordination for emergency preparedness and response activities across the agency, as well 
as with local, state, tribal, national, territorial, and international public health partners.
CDC also works with other federal agencies and intelligence authorities to ensure that authorities 
are apprised of all novel threats (engineered and natural) and retains world-class expertise in 
detecting, preventing, and controlling BT, CT, and RT agents. 
To meet these goals, CDC supports LRN, an integrated network of state and local public health, 
federal, military, and international laboratories that operates 24/7 to respond to BT and CT and 
other public health threats and emergencies. LRN protects the health and security of U.S. citizens 
and armed forces, providing essential information on human and animal exposures to enable 
health officials to react appropriately to threats, including deployment of medical 
countermeasures. LRN identifies the threat agents, who has been exposed and how severely, and 
the geographical extent of exposure to facilitate reactive and preemptive actions. CDC also 
promotes laboratory biosafety and biosecurity by administering the HHS Select Agent Program 
(42 CFR Part 73, available at http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&tpl=/
ecfrbrowse/Title42/42cfr73_main_02.tpl), which regulates throughout the United States the 
possession, use, and transfer of BT and toxins that can pose a severe threat to public health and 
safety. In the absence of these critical programs, the use, movement, and presence of these BT
threat agents would be unmonitored and could allow their intentional use as a biologic weapon to 
go undetected.
Selected Laboratory Activities in FY2011
CDC laboratories





























   
  
—	 developing reagents and assays for BT and emerging threats, including a mass 
spectrometry method for detecting anthrax lethal factor (a component of anthrax toxin) 
that detects disease 24 hours before symptoms; methods to quantify clinically relevant 
levels of botulinum neurotoxins in serum and feces; methods to determine botulinum 
toxin subtypes A and B (used to identify a previously unknown subtype); a rapid point-
of-care test for plague and other BT agents;
—	 providing consultation and confirmatory testing for the U.S. Department of Homeland 
Security BioWatch program, which detects environmentally dispersed BT agents, 
including the bacterium that causes anthrax;
—	 ensuring safe and secure working conditions within biosafety level-4 containment 

facilities for scientists working with high-consequence pathogens and VB agents; 

—	 enhancing preparedness to respond to outbreaks of high-consequence pathogens through 
test development and demonstration of efficacy for prophylaxis or postexposure
treatments, including various therapeutic interventions for treatment of orthopoxvirus 
infections (e.g., attributable to vaccine-related adverse events or to smallpox);
—	 providing instruction to more than 3,000 sentinel laboratory personnel from local public 
health, hospital and clinical laboratories in Rule-Out-and-Refer protocols and in 
laboratory safety and security protocols, including safe handling, packaging, and shipping
of potentially dangerous specimens;
—	 conducting intensive, hands-on trainings for 28 LRN reference laboratories in rapid 
detection and identification of BT agents; 
—	 ensuring laboratory performance and timely response to a biologic terrorism incident by
conducting BT response team exercises, developing and distributing quality-control 
materials, providing quality-assurance and performance testing to laboratories, and 
coordinating with federal partners through the Integrated Consortium of Laboratory
Networks; and
—	 processing 1,530 individual test results reported by 143 laboratories (out of 162 LRN 
laboratories) participating in the LRN BT proficiency testing program and certifying that 
LRN BT laboratories are qualified to measure biologic threat agents during a public 
health response.
•	 strengthened the chemical component of LRN by
—	 maintaining round-the-clock laboratory response capability, expanding surge capacity, 
























   
  
—	 ensuring laboratory performance and timely response to a chemical terrorism incident by
conducting CT response team exercises, developing and distributing quality-control 
materials, providing quality-assurance and performance testing to laboratories, and 
coordinating with federal partners through the Integrated Consortium of Laboratory
Networks;
—	 processing 11,500 individual test results reported by 46 state public health laboratories 
participating in the LRN proficiency testing program and certifying that LRN laboratories 
are qualified to measure CT agents during a public health response; 
•	 developed new analytic methods for the urine radionuclide screen, thereby strengthening
CDC laboratory capacity to assess radiologic exposure of persons during RT events, 
including exposures to low-grade nuclear bombs, industrial unintentional incidents, 
thermonuclear devices, and radionuclides that cannot be detected by Geiger counters or by
clinical assessment (e.g., exposures to uranium-235, strontium, plutonium-238, and radium);
•	 investigated and identified low levels of radiation exposure among U.S. residents working in 
Japan after release of radiation from the Fukushima Daiichi Nuclear Power Plant by using the 
urine radionuclide screen;
•	 executed regulatory and statutory responsibilities for the HHS Select Agent Program (42 
CFR Part 73, available at http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&tpl=/
ecfrbrowse/Title42/42cfr73_main_02.tpl), the CDC Import Permit Program (42 CFR Part 
71.54, available at http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=d53e3b1
b73bd80865fb0a044f8be8c1d&rgn=div8&view=text&node=42:1.0.1.6.59.6.19.4&idno=42), 
the Foreign Quarantine Regulations, the Bioterrorism Response Act of 2002, and the 
PATRIOT Act. CDC regulates more than 325 entities that use, possess, or transfer Select 
Agents within the United States and processes more than 1,500 import permits per year to 
prevent bioterrorism events within the United States (e.g., the anthrax attacks of October 
2001). 
•	 improved analysis and messaging of BT, CT, and RT data by
—	 assisting states in implementing laboratory information management systems that 

increase the speed and accuracy of data transfer;
 
—	 disseminating customized software that promotes use of common definitions of BT
events by all LRN laboratories; and 
—	 developing a communications channel for addressing delays and difficulties in 
disseminating test information (e.g., results, test specifics, and specimen types) within the 














•	 supported a cross-cutting program that provides infrastructure, diagnostic, reference, 
research, reagent production, and surveillance programs to CDC laboratories; the unique 
services provided are essential to the daily operations of the laboratories and include 
veterinary and animal husbandry, centralized specimen management, and support to CDC 
scientists in genomics, proteomics, bioinformatics, chemical synthesis, and other scientific 
disciplines; 
•	 confirmed exposures among Alaska residents to saxitoxin, a neurotoxin located in shellfish 
exposed to toxic algal blooms; 
•	 helped identify the source of the 2011 cholera outbreak in Haiti by using next-generation 
whole genome sequencing data; 
•	 produced biologic products, reagents, kits, and cell cultures to provide immediate readiness 
to meet the needs of CDC laboratories, ongoing influenza surveillance projects, and LRN 
(e.g., test kits for anthrax and botulism detection, as well as influenza serotyping); and
•	 managed a memorandum of understanding established with the Office of In-Vitro Diagnostic 
Device Evaluation and Safety at FDA for the 1-year assignment of a CDC scientist to FDA to 
learn about regulatory 510(k) requirements for laboratory-developed tests and in vitro



































List of Abbreviations Used in This Report 
ACIP Advisory Committee on Immunization Practices
AIDS acquired immunodeficiency syndrome
AR antimicrobial resistance 
BA budget authority
BT biologic threat
CDC Centers for Disease Control and Prevention 
CFS chronic fatigue syndrome
CT chemical threat
FDA Food and Drug Administration 
FY Fiscal Year 
GDD Global Disease Detection 
HBV hepatitis B virus
HCV hepatitis C virus
HDL high-density lipoprotein
HHV-8 human herpes virus type 8 
HIV human immunodeficiency virus 
HPV human papillomavirus
IHR International Health Regulations
LD Lyme disease
LDL low-density lipoprotein
LRN Laboratory Response Network 
MDR TB multidrug-resistant tuberculosis 
MRSA methicillin-resistant Staphylococcus aureus
NBDPS National Birth Defects Prevention Study 
NHANES National Health and Nutrition Examination Survey
PEPFAR President’s Emergency Plan for AIDS Relief
PFOS perfluorooctane sulfonic acid 
RT radiologic threat
SARS severe acute respiratory syndrome
SCID severe combined immunodeficiency 
STD sexually transmitted disease
TB tuberculosis
TSNAs tobacco-specific nitrosamines 
USAID U.S. Agency for International Development
USDA U.S. Department of Agriculture 
VB vectorborne
WHO World Health Organization 
XDR TB extensively drug-resistant tuberculosis 
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